Articles tagged "Immunosuppression"

2021 American Transplant Congress
Impact of New Onset Diabetes After Transplantation on Heart Transplant Recipients
W. Kang¹, W. Keattiyoat², M. Kim¹, C. Bhardwaj²
¹Department of Internal Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL, ²Department of Cardiology, University of Illinois College of Medicine at Peoria, Peoria, IL
*Purpose: The purpose of this study is to investigate New Onset Diabetes After Transplantation (NODAT) incidence and its impact on post-transplant prognosis in adult heart…
2021 American Transplant Congress
A Question with Multiple Answers: Do Renal Transplant Recipients Require Steroid Maintenance Following Thymoglobulin Induction?
A. Aala, H. Patel, F. Cardarelli
Beth Israel Deaconess Medical Center, Boston, MA
*Purpose: Anti-thymocyte globulin (ATG) has been used with good results in renal transplantation as induction therapy, followed by triple immunosuppression with calcineurin inhibitors, antimetabolites, and…
2021 American Transplant Congress
Use of Donor-Derived Cell-Free DNA for Assessment of Allograft Rejection After Change in Maintenance Immunosuppression Regimens in the First Year Post Kidney Transplant
M. Walsh, V. Peev, L. Lineberger, M. Brokhof, N. Kenyon, N. Alvey
Rush University Medical Center, Chicago, IL
*Purpose: The purpose of this study was to investigate whether the use of donor-derived cell-free DNA (dd-cfDNA) is an effective screening tool for allograft rejection…
2021 American Transplant Congress
Bamlanivimab for Covid-19 in Kidney Transplant Patients
M. Y. Jan, S. El-Sayegh, M. S. Yaqub, D. P. Mishler, O. Adebiyi, M. D. Anderson, T. E. Taber, A. Sharfuddin
Nephrology, Indiana University School of Medicine, Indianapolis, IN
*Purpose: Treatment options for patients with COVID 19 have limited efficacy in reducing severity and duration of viral symptoms as well as progression to severe…
2021 American Transplant Congress
Peripheral Blood Hematopoietic Chimerism: A Robust Biomarker for Transplantation Tolerance
D. Tollerud¹, E. Gornstein¹, J. Leventhal², K. V. Ravindra³, S. Ildstad¹
¹Talaris Therapeutics, Louisville, KY, ²Division of Organ Transplantation, Northwestern Medical Group, Chicago, IL, ³Department of Surgery, Duke University Medical Center, Durham, NC
*Purpose: Despite the development of highly effective immunosuppressive medications, organ rejection and the toxicity of the drugs themselves remain significant obstacles to long-term graft and…
2021 American Transplant Congress
Impact Analysis of Virtual Transplant Ambulatory Pharmacist During Covid-19
L. Park, G. Waldman, J. Kim, C. Rogers, J. Clark
Massachusetts General Hospital, Boston, MA
*Purpose: During the COVID-19 pandemic, transplant centers were challenged to meet the demand for new telemedicine strategies. High-risk immunocompromised patients, such as lung transplant recipients…
2021 American Transplant Congress
Adenovirus-Specific T Cells for Steering of Immunosuppression After Pediatric Kidney Transplantation in the Randomized Controlled Ivist Trial
T. Ahlenstiel-Grunow¹, X. Liu², R. Schild³, J. Oh³, C. Taylan⁴, L. T. Weber⁴, H. Staude⁵, M. Verboom⁶, C. Schröder⁷, R. Sabau⁷, A. Großhennig², L. Pape¹
¹Pediatrics II, University Hospital of Essen, Essen, Germany, ²Institute of Biostatistics, Hannover Medical School, Hannover, Germany, ³Pediatric Nephrology, University Hospital Hamburg-Eppendorf, Hamburg, Germany, ⁴Pediatric Nephrology, University of Colgne, Köln, Germany, ⁵Pediatric Nephrology, University Hospital of Rostock, Rostock, Germany, ⁶Institute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, Hannover, Germany, ⁷Institute for Clinical Pharmacology, Hannover Medical School, Hannover, Germany
*Purpose: Pharmacokinetic monitoring alone is insufficient to estimate the intensity of immunosuppression after pediatric kidney transplantation (Tx). Levels of virus-specific T cells (Tvis) have been…
2021 American Transplant Congress
Harnessing Innate Lymphoid Cells to Prevent Graft-versus Host Disease
K. T. Reid¹, S. Q. Crome²
¹Immunology, University of Toronto, Toronto, ON, Canada, ²Ajmera Transplant Centre, TGHRI, University Health Network, Toronto, ON, Canada
*Purpose: Determine whether human innate lymphoid cells (ILCs) can be isolated, expanded and used in cell-based therapies to prevent Graft-versus Host Disease (GvHD) .*Methods: ILC2s…
2021 American Transplant Congress
Clinical Consequences in Patients Experiencing Leukopenia and Neutropenia After Solid Organ Transplant
A. Diamond¹, N. Diehl², K. Hiryak³, K. Mortia¹, J. Au¹, C. Ruggia-Check¹, H. Clauss⁴
¹Pharmacy, Temple University Hospital, Philadelphia, PA, ²Pharmacy, UPMC Pinnacle Health, Harrisburg, PA, ³Pharmacy, Temple University School of Pharmacy, Philadelphia, PA, ⁴Infectious Diseases, Temple University Hospital, Philadelphia, PA
*Purpose: The incidence of leukopenia and neutropenia in solid organ transplant (SOT) recipients can be influenced by medications required after transplant for immunosuppression and infection…
2021 American Transplant Congress
Sirolimus (srl) versus Everolimus (evr) versus Mycophenolate (mpa) in Kidney Transplant Recipients Receiving Anti-thymocyte Globulin Induction (r-atg), Tacrolimus (tac), and Prednisone
H. Tedesco Silva Junior, C. Felipe, L. Viana, M. Cristelli, N. Tenorio, V. Lima, V. Azevedo, K. Ficher, J. Rezende, R. Foresto, M. Nakamura, Y. Dreige, J. Taddeo, C. Zito, J. Medina
Hospital do Rim, Universidade Federal de São Paulo, São Paulo, Brazil
*Purpose: The aim of this study is to compare the efficacy and safety of SRL versus EVR versus MPA in kidney transplant recipients.*Methods: This is…